ArticleCureus2025
An Unusual Therapy for an Atypical Case of Secondary Extranodal, Non-parenchymal Central Nervous System Marginal Zone Lymphoma.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Marginal zone lymphomas (MZL) are low-grade B-cell neoplasms with indolent clinical behavior and a favorable prognosis. Central nervous system (CNS) involvement is extremely rare in MZL, as in other low-grade lymphomas where some presented with primary CNS disease without involvement elsewhere, and only a few cases were secondary to MZL. The dura mater is the most common site of involvement, while cavernous sinus involvement is extremely rare. There are no specific treatment recommendations for patients with secondary CNS-MZL exhibiting an indolent course. Therapeutic trials and recommendations typically focus on aggressive lymphomas with a poor prognosis, where induction with intensive chemotherapy, including high-dose methotrexate and/or cytarabine, followed by autologous stem cell transplantation, is standard. We present the case of a 50-year-old man with MZL involving the cavernous sinus, who initially presented with neurological and ophthalmological symptoms and was successfully treated with high-dose methotrexate and the CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) regimen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.